Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Atara Biotherapeutics $100 million at-the-market offering
The stock is listed on Nasdaq
Smith+Nephew acquisition of CartiHeal
We are advising Smith+Nephew on the acquisition
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Amneal Pharmaceuticals $2.35 billion term loan
We advised Amneal Pharmaceuticals on a new term loan
Mallinckrodt emerges from chapter 11
We advised an ad hoc group of first-lien noteholders
Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
Alector $125 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
NeuroPace $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
GSK exclusive license agreement for HS-20089 with Hansoh Pharma
We advised GSK on the transaction